Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023
M2 - 2 hrs 12 mins ago
Research and Markets (http://www.researchandmarkets.com/research/d7b94m/cariprazine) has announced the addition of the "Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023" report to their offering. Cariprazine (RGH-188) is being developed as an adjunctive treatment to antidepressant therapy in patients with MDD who had an inadequate response to antidepressant therapy, and as of April 2014, two Phase III clinical trials were ongoing (Forest Laboratories, NCT01715805; Forest Laboratories, NCT01838876). In addition, cariprazine is being developed for the treatment of schizophrenia and bipolar disorder. Scope - Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Cariprazine including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Cariprazine for the top eight countries from 2013 to 2023. - Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview - Etiology and Pathophysiology - Classification - Symptoms and Subtypes of Major Depressive Disorder - Prognosis - Quality of Life 4 Disease Management - Diagnosis - Treatment Guidelines and Leading Prescribed Drugs - Clinical Practice 5 Competitive Assessment 6 Unmet Needs and Opportunities - More Effective Pharmacotherapies - More Favorable Side Effect Profiles - Rapid Onset of Antidepressant Effects - Personalized Treatment Approach 7 Pipeline Assessment 8 Cariprazine (RGH-188) 9 Appendix For more information visit http://www.researchandmarkets.com/research/d7...ariprazine
Forest Laboratories Nabs Pediatric Exclusivity for Namenda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 12:20PM CDT
With an additional six months of pediatric exclusivity in the U.S., generic versions of Forest's (FRX) Namenda IR will now enter the market in Jul 2015.
Will Forest Laboratories (FRX) Crush Estimates at Its Next Earnings Report? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 7:50AM CDT
Recent estimates have been moving higher for Forest Laboratories.
Forest Laboratories acquires extended US market pediatric exclusivity for NAMENDA and NAMENDA XR by six months
M2 - Thu Jun 19, 4:56AM CDT
Pharmaceutical company Forest Laboratories (NYSE:FRX) said on Wednesday that it has received the US Food and Drug Administration's (FDA) pediatric exclusivity for memantine hydrochloride.
Nasdaq, S&P 500 Rally To New Highs After Fed Meeting
at Investor's Business Daily - Wed Jun 18, 3:20PM CDT
The major averages rallied after the Fed said it would keep interest rates near zero and trimmed monthly bond purchases by $10 billion, to $35 billion. The Fed lowered its 2014 economic growth forecast to between 2.1% and 2.3%, from 2.9%, but said...
Next Resistance Level for Forest Laboratories (FRX) is $99.30
Comtex SmarTrend(R) - Wed Jun 18, 9:02AM CDT
Shares of Forest Laboratories (NYSE:FRX) have bullishly opened above the pivot of $96.19 today and have reached the first resistance level of $97.94. Analysts will be watching for a cross of the next upside pivot targets of $99.30 and $102.41.
Forest Obtains Six Months U.S. Pediatric Exclusivity for NAMENDA(R) and NAMENDA XR(R)
Business Wire - Wed Jun 18, 7:30AM CDT
Forest Laboratories, Inc. (NYSE:FRX) announced today that the U.S Food and Drug Administration (FDA) has granted pediatric exclusivity for memantine hydrochloride. Based on this decision, an additional six months of U.S. market exclusivity will attach to the patents that are listed in FDA's Orange Book for NAMENDA and NAMENDA XR.
Allergan, Actavis Top Big Cap Pharmas Amid M&A Flurry
at Investor's Business Daily - Wed Jun 18, 7:02AM CDT
With 2014 already the strongest year for mergers and acquisitions since 2007, the flurry of dealmaking has given shares of some large drugmakers a shot in the arm -- or face, in the case of Botox maker Allergan (AGN). But not all offers have been...
PharmaPoint: Major Depressive Disorder Report 2014 - Current and Future Players
M2 - Wed Jun 18, 4:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wdh27g/pharmapoint) has announced the addition of the "PharmaPoint: Major Depressive Disorder - Current and Future Players" report to their offering. The report identifies and analyses the key companies shaping and driving the global Major Depressive Disorder market. The report provides insight into the competitive Major Depressive Disorder landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by Our team of industry experts. Scope - Investigation of current and future market competition for Major Depressive Disorder. - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Major Depressive Disorder sector through market impact analysis, future market scenario and company analysis Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Market Outlook - Forecast - Drivers and Barriers - Global Issues 4 Current and Future Players - Trends in Corporate Strategy - Company Profiles 5 Appendix Companies Mentioned - Lundbeck - Forest Laboratories (Actavis) - Eli Lilly - Pfizer - Otsuka Pharmaceutical - AstraZeneca - Takeda Pharmaceutical - Alkermes - Euthymics Bioscience - Naurex - e-Therapeutics For more information visit http://www.researchandmarkets.com/research/wd...harmapoint
Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023
M2 - Wed Jun 18, 3:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5mvpkt/viibryd_major) has announced the addition of the "Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023" report to their offering. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023. Viibryd (vilazodone) is an SSRI and a 5HT1A receptor partial agonist indicated for the treatment of patients with MDD. Viibryd was licensed from Merck KGaA and developed by Forest (Actavis). Currently, it is only available in the US market and, in 2013, generated sales of $162.5m (Forest Laboratories, 2014). Scope - Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Viibryd including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Viibryd for the US from 2013 to 2023. - Sales information covered for the US. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Viibryd (Vilazodone) 7 Appendix For more information visit http://www.researchandmarkets.com/research/5m...bryd_major
Actavis' shareholders approves planned acquisition of Forest for about USD25bn in cash and stock
M2 - Wed Jun 18, 3:52AM CDT
Specialist pharmaceutical company Actavis (NYSE:ACT) stated on Tuesday that all proposals related to its planned acquisition of Forest Laboratories (NYSE:FRX) were approved by their respective shareholders at the recent shareholder meetings.
Actavis and Forest Shareholders Approve Proposals Related to Actavis' Planned Acquisition of Forest
Business Wire - Tue Jun 17, 3:17PM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that, at shareholder meetings held today, all proposals related to Actavis' planned acquisition of Forest were approved by both Actavis' and Forest's shareholders.
Valeant Receives FDA's Clearance for Restylane - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 2:05PM CDT
Valeant Pharmaceuticals International, Inc. (VRX) announced that the FDA issued a marketing clearance for its Restylane Silk Injectable Gel with 0.3% Lidocaine.
Global Autism Clinical Trials Review 2014
M2 - Tue Jun 17, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vhfbw6/autism_global) has announced the addition of the "Autism Global Clinical Trials Review, H1, 2014" report to their offering. Autism Global Clinical Trials Review, H1, 2014 provides data on the Autism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Autism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Autism. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Autism Speaks, Inc. - Seaside Therapeutics, LLC - Forest Laboratories, Inc. - Johnson & Johnson - Otsuka Holdings Co., Ltd. - F. Hoffmann-La Roche Ltd. - Bristol-Myers Squibb Company - Coronado Biosciences, Inc. - ZonMw - Dainippon Sumitomo Pharma Co., Ltd. - National Institute of Mental Health - Massachusetts General Hospital - Tehran University of Medical Sciences - Eunice Kennedy Shriver National Institute of Child Health and Human Development - Hugo W. Moser Research Institute at Kennedy Krieger, Inc. - Stanford University - The University of Hong Kong - University of California, Los Angeles - Mount Sinai Hospital - University of California, San Francisco For more information visit http://www.researchandmarkets.com/research/vh...ism_global
COPD Foundation Releases Groundbreaking COPE Survey Results: Low Patient Awareness About COPD Exacerbations Poses Barrier to Effective Management
Business Wire - Tue Jun 17, 8:37AM CDT
Patients with chronic obstructive pulmonary disease (COPD) may need more education and better dialogue with their physicians to effectively manage the progressive respiratory condition and potentially life-threatening complications known as exacerbations (or flare-ups), according to key findings from the new, two-part national COPE (Chronic Obstructive Pulmonary Experience) Survey initiative released today by the COPD Foundation.
Fetzima (Major Depressive Disorder) - Forecast and Market Analysis to 2023
M2 - Tue Jun 17, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lnvwv5/fetzima_major) has announced the addition of the "Fetzima (Major Depressive Disorder) - Forecast and Market Analysis to 2023" report to their offering. Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023. Fetzima (levomilnacipran) is an SNRI indicated for the treatment of MDD and is only available in the US. It gained FDA approval in July 2013 and was launched in December 2013. The product was developed by Forest (Actavis) following a partnership with Pierre Fabre. According to this agreement, Forest Laboratories is responsible for the clinical development and commercialization of Fetzima in the US and Canada, while Pierre Fabre is responsible for manufacturing and supplying the active pharmaceutical ingredient. Scope - Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Fetzima including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Fetzima for the US from 2013 to 2023. - Sales information covered for the US. Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Fetzima (Levomilnacipran) 7 Appendix For more information visit http://www.researchandmarkets.com/research/ln...zima_major
Idiopathic (Essential) Hypertension - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h6fdl5/idiopathic) has announced the addition of the "Idiopathic (Essential) Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic (Essential) Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic (Essential) Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Idiopathic (Essential) Hypertension - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Idiopathic (Essential) Hypertension pipeline depth and focus of Indication therapeutics Companies Mentioned: - Novartis AG - Actelion Ltd - Forest Laboratories, Inc. - Les Laboratoires Servier SAS - Bayer AG - XOMA Corporation - Ahn-Gook Pharmaceutical Co., Ltd. - PhaseBio Pharmaceuticals, Inc. - Lee's Pharmaceutical Holdings Limited - NanoForm Therapeutics Ltd. For more information visit http://www.researchandmarkets.com/research/h6fdl5/idiopathic
Will Forest Labs Retain Namenda Market Share? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 11:00AM CDT
Forest Laboratories, Inc. (FRX) has postponed the final phase of switching to late 2014 and intends to continue marketing Namenda IR till the fall of 2014.
Actavis Announces Receipt of Requisite Consents and Expiration of Consent Solicitations for Forest Laboratories Senior Notes
PR Newswire - Thu Jun 12, 5:16PM CDT
Actavis plc (NYSE: ACT) today announced that Forest Laboratories, Inc. (NYSE: FRX) has received valid consents (the "Requisite Consents"